Review



3852 pi  (Biosynth Carbosynth)


Bioz Verified Symbol Biosynth Carbosynth is a verified supplier
Bioz Manufacturer Symbol Biosynth Carbosynth manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Biosynth Carbosynth 3852 pi
    3852 Pi, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 90/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/3852 pi/product/Biosynth Carbosynth
    Average 90 stars, based on 2 article reviews
    3852 pi - by Bioz Stars, 2026-02
    90/100 stars

    Images



    Similar Products

    3852 pi  (Biosynth Carbosynth)
    90
    Biosynth Carbosynth 3852 pi
    3852 Pi, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/3852 pi/product/Biosynth Carbosynth
    Average 90 stars, based on 1 article reviews
    3852 pi - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    tapi2  (Biosynth Carbosynth)
    90
    Biosynth Carbosynth tapi2

    Tapi2, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tapi2/product/Biosynth Carbosynth
    Average 90 stars, based on 1 article reviews
    tapi2 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    non specific adam17 inhibitor tapi 2  (Biosynth Carbosynth)
    90
    Biosynth Carbosynth non specific adam17 inhibitor tapi 2
    Fig. 4 ADAM10 or <t>ADAM17</t> inhibition increases cell migration out of tumourspheres on three different ECMs. Tumoursphere spreading assay: Individual tumourspheres (100 μm in diameter) were incubated with 1 μM Ara-C and either IgG (2 μg/ ml), anti-ADAM10 (0.2 μg/ml), anti-ADAM17 (2 μg/ml) or anti- ADAM10 and ADAM17 combined. Spheres were imaged five times at regular intervals between t = 0 h and t = 45 h; sphere area was measured using Image J. Cell migration out of the sphere was calculated as ((t- = 45 h −t = 0 h)/t = 0 h) × 100 to give percent increase in sphere area. a Phase contrast images of sphere migration from a single G065 sphere on LN at 0 h, 20 h and 45 h, scale bar = 100 μm. b Cell migration out of G065 spheres was tested on wells pre- coated with three ECMs; laminin (LN), fibronectin (FN) or vitronectin (VN) at 25 μg/ml. N = 4–6 spheres per condition; *P < 0.05 using one-way ANOVA followed by Bonferroni’s posthoc test. c Cell migration out of G002 spheres was tested on wells pre-coated with FN (25 μg/ml), N = 4–6 spheres per condition; P > 0.05 using one-way ANOVA. d Cell migration out of G002 spheres on fibronectin in the absence or presence of growth factors (GF) when treated with IgG only. N = 5–6 spheres per condition; **P < 0.0001 using unpaired t test
    Non Specific Adam17 Inhibitor Tapi 2, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/non specific adam17 inhibitor tapi 2/product/Biosynth Carbosynth
    Average 90 stars, based on 1 article reviews
    non specific adam17 inhibitor tapi 2 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    tapi 2 peptide  (Biosynth Carbosynth)
    90
    Biosynth Carbosynth tapi 2 peptide
    Fig. 4 ADAM10 or <t>ADAM17</t> inhibition increases cell migration out of tumourspheres on three different ECMs. Tumoursphere spreading assay: Individual tumourspheres (100 μm in diameter) were incubated with 1 μM Ara-C and either IgG (2 μg/ ml), anti-ADAM10 (0.2 μg/ml), anti-ADAM17 (2 μg/ml) or anti- ADAM10 and ADAM17 combined. Spheres were imaged five times at regular intervals between t = 0 h and t = 45 h; sphere area was measured using Image J. Cell migration out of the sphere was calculated as ((t- = 45 h −t = 0 h)/t = 0 h) × 100 to give percent increase in sphere area. a Phase contrast images of sphere migration from a single G065 sphere on LN at 0 h, 20 h and 45 h, scale bar = 100 μm. b Cell migration out of G065 spheres was tested on wells pre- coated with three ECMs; laminin (LN), fibronectin (FN) or vitronectin (VN) at 25 μg/ml. N = 4–6 spheres per condition; *P < 0.05 using one-way ANOVA followed by Bonferroni’s posthoc test. c Cell migration out of G002 spheres was tested on wells pre-coated with FN (25 μg/ml), N = 4–6 spheres per condition; P > 0.05 using one-way ANOVA. d Cell migration out of G002 spheres on fibronectin in the absence or presence of growth factors (GF) when treated with IgG only. N = 5–6 spheres per condition; **P < 0.0001 using unpaired t test
    Tapi 2 Peptide, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tapi 2 peptide/product/Biosynth Carbosynth
    Average 90 stars, based on 1 article reviews
    tapi 2 peptide - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    tapi 2  (Biosynth Carbosynth)
    90
    Biosynth Carbosynth tapi 2
    Fig. 4 ADAM10 or <t>ADAM17</t> inhibition increases cell migration out of tumourspheres on three different ECMs. Tumoursphere spreading assay: Individual tumourspheres (100 μm in diameter) were incubated with 1 μM Ara-C and either IgG (2 μg/ ml), anti-ADAM10 (0.2 μg/ml), anti-ADAM17 (2 μg/ml) or anti- ADAM10 and ADAM17 combined. Spheres were imaged five times at regular intervals between t = 0 h and t = 45 h; sphere area was measured using Image J. Cell migration out of the sphere was calculated as ((t- = 45 h −t = 0 h)/t = 0 h) × 100 to give percent increase in sphere area. a Phase contrast images of sphere migration from a single G065 sphere on LN at 0 h, 20 h and 45 h, scale bar = 100 μm. b Cell migration out of G065 spheres was tested on wells pre- coated with three ECMs; laminin (LN), fibronectin (FN) or vitronectin (VN) at 25 μg/ml. N = 4–6 spheres per condition; *P < 0.05 using one-way ANOVA followed by Bonferroni’s posthoc test. c Cell migration out of G002 spheres was tested on wells pre-coated with FN (25 μg/ml), N = 4–6 spheres per condition; P > 0.05 using one-way ANOVA. d Cell migration out of G002 spheres on fibronectin in the absence or presence of growth factors (GF) when treated with IgG only. N = 5–6 spheres per condition; **P < 0.0001 using unpaired t test
    Tapi 2, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tapi 2/product/Biosynth Carbosynth
    Average 90 stars, based on 1 article reviews
    tapi 2 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    inh 3852 pi  (Biosynth Carbosynth)
    90
    Biosynth Carbosynth inh 3852 pi
    Fig. 4 ADAM10 or <t>ADAM17</t> inhibition increases cell migration out of tumourspheres on three different ECMs. Tumoursphere spreading assay: Individual tumourspheres (100 μm in diameter) were incubated with 1 μM Ara-C and either IgG (2 μg/ ml), anti-ADAM10 (0.2 μg/ml), anti-ADAM17 (2 μg/ml) or anti- ADAM10 and ADAM17 combined. Spheres were imaged five times at regular intervals between t = 0 h and t = 45 h; sphere area was measured using Image J. Cell migration out of the sphere was calculated as ((t- = 45 h −t = 0 h)/t = 0 h) × 100 to give percent increase in sphere area. a Phase contrast images of sphere migration from a single G065 sphere on LN at 0 h, 20 h and 45 h, scale bar = 100 μm. b Cell migration out of G065 spheres was tested on wells pre- coated with three ECMs; laminin (LN), fibronectin (FN) or vitronectin (VN) at 25 μg/ml. N = 4–6 spheres per condition; *P < 0.05 using one-way ANOVA followed by Bonferroni’s posthoc test. c Cell migration out of G002 spheres was tested on wells pre-coated with FN (25 μg/ml), N = 4–6 spheres per condition; P > 0.05 using one-way ANOVA. d Cell migration out of G002 spheres on fibronectin in the absence or presence of growth factors (GF) when treated with IgG only. N = 5–6 spheres per condition; **P < 0.0001 using unpaired t test
    Inh 3852 Pi, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/inh 3852 pi/product/Biosynth Carbosynth
    Average 90 stars, based on 1 article reviews
    inh 3852 pi - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Journal: iScience

    Article Title: Heightened innate immune state induced by viral vector leads to enhanced response to challenge and prolongs malaria vaccine protection

    doi: 10.1016/j.isci.2024.111468

    Figure Lengend Snippet:

    Article Snippet: TAPI2 , Biosynth , Cat #INH-3852-PI.

    Techniques: Control, Virus, Recombinant, Giemsa Stain, Cell Stimulation, Transfection, Software

    Fig. 4 ADAM10 or ADAM17 inhibition increases cell migration out of tumourspheres on three different ECMs. Tumoursphere spreading assay: Individual tumourspheres (100 μm in diameter) were incubated with 1 μM Ara-C and either IgG (2 μg/ ml), anti-ADAM10 (0.2 μg/ml), anti-ADAM17 (2 μg/ml) or anti- ADAM10 and ADAM17 combined. Spheres were imaged five times at regular intervals between t = 0 h and t = 45 h; sphere area was measured using Image J. Cell migration out of the sphere was calculated as ((t- = 45 h −t = 0 h)/t = 0 h) × 100 to give percent increase in sphere area. a Phase contrast images of sphere migration from a single G065 sphere on LN at 0 h, 20 h and 45 h, scale bar = 100 μm. b Cell migration out of G065 spheres was tested on wells pre- coated with three ECMs; laminin (LN), fibronectin (FN) or vitronectin (VN) at 25 μg/ml. N = 4–6 spheres per condition; *P < 0.05 using one-way ANOVA followed by Bonferroni’s posthoc test. c Cell migration out of G002 spheres was tested on wells pre-coated with FN (25 μg/ml), N = 4–6 spheres per condition; P > 0.05 using one-way ANOVA. d Cell migration out of G002 spheres on fibronectin in the absence or presence of growth factors (GF) when treated with IgG only. N = 5–6 spheres per condition; **P < 0.0001 using unpaired t test

    Journal: Molecular neurobiology

    Article Title: Metalloproteinases ADAM10 and ADAM17 Mediate Migration and Differentiation in Glioblastoma Sphere-Forming Cells.

    doi: 10.1007/s12035-016-0053-6

    Figure Lengend Snippet: Fig. 4 ADAM10 or ADAM17 inhibition increases cell migration out of tumourspheres on three different ECMs. Tumoursphere spreading assay: Individual tumourspheres (100 μm in diameter) were incubated with 1 μM Ara-C and either IgG (2 μg/ ml), anti-ADAM10 (0.2 μg/ml), anti-ADAM17 (2 μg/ml) or anti- ADAM10 and ADAM17 combined. Spheres were imaged five times at regular intervals between t = 0 h and t = 45 h; sphere area was measured using Image J. Cell migration out of the sphere was calculated as ((t- = 45 h −t = 0 h)/t = 0 h) × 100 to give percent increase in sphere area. a Phase contrast images of sphere migration from a single G065 sphere on LN at 0 h, 20 h and 45 h, scale bar = 100 μm. b Cell migration out of G065 spheres was tested on wells pre- coated with three ECMs; laminin (LN), fibronectin (FN) or vitronectin (VN) at 25 μg/ml. N = 4–6 spheres per condition; *P < 0.05 using one-way ANOVA followed by Bonferroni’s posthoc test. c Cell migration out of G002 spheres was tested on wells pre-coated with FN (25 μg/ml), N = 4–6 spheres per condition; P > 0.05 using one-way ANOVA. d Cell migration out of G002 spheres on fibronectin in the absence or presence of growth factors (GF) when treated with IgG only. N = 5–6 spheres per condition; **P < 0.0001 using unpaired t test

    Article Snippet: To inhibit ADAM10 and ADAM17 in vitro, we used antibodies against hADAM10 (Millipore #AB19026) and hADAM17 (Calbiochem #PC491) and the non-specific ADAM17 inhibitor TAPI-2 (Peptides International #INH3852-PI).

    Techniques: Inhibition, Migration, Incubation

    Fig. 6 GSC adhesion to fibronectin is mediated by integrin α5β1 and interaction with ADAM10 and ADAM17. Adhesion of GSCs to fibronectin over 1.5 h. Dissociated cells from G100 GSC line were incubated with antibodies blocking α (a) or β (b) integrins and IgG isotype control. N = 6–8 wells per condition; **P < 0.01, ***P < 0.001 compared to IgG control, using one-way ANOVA followed by Tukey’s posthoc test. Expression of β1 integrin (c) and DAPI (d) in G100 tumoursphere adhered to fibronectin; scale bar =30 μm. (e–f) Adhesion of G100 GSCs to fibronectin over 1.5 h. Cells were treated with β1- blocking antibody with either ADAM10 and ADAM17 blocking antibodies (e) or recombinant human (rh) ADAM10 and ADAM17 (f). N = 4–5 wells per condition (e), N = 8 wells per condition (f); *P < 0.05, **P < 0.01, ***P < 0.001 using one-way ANOVA followed by Tukey’s posthoc test

    Journal: Molecular neurobiology

    Article Title: Metalloproteinases ADAM10 and ADAM17 Mediate Migration and Differentiation in Glioblastoma Sphere-Forming Cells.

    doi: 10.1007/s12035-016-0053-6

    Figure Lengend Snippet: Fig. 6 GSC adhesion to fibronectin is mediated by integrin α5β1 and interaction with ADAM10 and ADAM17. Adhesion of GSCs to fibronectin over 1.5 h. Dissociated cells from G100 GSC line were incubated with antibodies blocking α (a) or β (b) integrins and IgG isotype control. N = 6–8 wells per condition; **P < 0.01, ***P < 0.001 compared to IgG control, using one-way ANOVA followed by Tukey’s posthoc test. Expression of β1 integrin (c) and DAPI (d) in G100 tumoursphere adhered to fibronectin; scale bar =30 μm. (e–f) Adhesion of G100 GSCs to fibronectin over 1.5 h. Cells were treated with β1- blocking antibody with either ADAM10 and ADAM17 blocking antibodies (e) or recombinant human (rh) ADAM10 and ADAM17 (f). N = 4–5 wells per condition (e), N = 8 wells per condition (f); *P < 0.05, **P < 0.01, ***P < 0.001 using one-way ANOVA followed by Tukey’s posthoc test

    Article Snippet: To inhibit ADAM10 and ADAM17 in vitro, we used antibodies against hADAM10 (Millipore #AB19026) and hADAM17 (Calbiochem #PC491) and the non-specific ADAM17 inhibitor TAPI-2 (Peptides International #INH3852-PI).

    Techniques: Incubation, Blocking Assay, Control, Expressing, Recombinant